Meitav Investment House’s NeuroSense Therapeutics NRSN Stock Holding History

Meitav Investment House’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40,000	Closed	-$30.2K	–	329
2026 Q1	$30.2K	Hold	40,000	–	–	﹤0.01%	231
2025 Q4	$30.8K	Hold	40,000	–	–	﹤0.01%	241
2025 Q3	$50K	Hold	40,000	–	–	﹤0.01%	236
2025 Q2	$75.6K	Hold	40,000	–	–	﹤0.01%	217
2025 Q1	$37.2K	Hold	40,000	–	–	﹤0.01%	216
2024 Q4	$48K	Hold	40,000	–	–	﹤0.01%	221
2024 Q3	$50.8K	Hold	40,000	–	–	﹤0.01%	227
2024 Q2	$44.8K	Sell	40,000 -10,000	-20%	-$12.7K	﹤0.01%	221
2024 Q1	$91K	Sell	50,000 -45,000	-47%	-$60.6K	﹤0.01%	229
2023 Q4	$74.6K	Hold	95,000	–	–	﹤0.01%	333
2023 Q3	$67.5K	Hold	95,000	–	–	﹤0.01%	332
2023 Q2	$142K	Hold	95,000	–	–	﹤0.01%	370
2023 Q1	$193K	Buy	+95,000	New	+$158K	﹤0.01%	348

Other funds holding NRSN

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Meitav Investment House's NRSN Position: Q2 2026 in Review

Meitav Investment House sold out of NeuroSense Therapeutics (NRSN) in Q2 2026, closing a stake of 40,000 shares — an estimated $30.2K sold.

Meitav Investment House first reported a position in NRSN in Q1 2023 and held it in 13 quarters. The position peaked at $193K in Q1 2023. 4 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

Meitav Investment House reported no remaining NeuroSense Therapeutics position as of Q2 2026 after selling out during the quarter.
Meitav Investment House sold 40,000 NeuroSense Therapeutics shares in Q2 2026, an estimated $30.2K.
Meitav Investment House first reported a position in NeuroSense Therapeutics in Q1 2023 and held it in 13 quarters.
Meitav Investment House's NeuroSense Therapeutics position peaked at $193K in Q1 2023.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Meitav Investment House's 13F filing for Q2 2026, filed 20 Jul 2026.